Risk factors for hyperbilirubinemia during glecaprevir/pibrentasvir treatment

Aimono Yuka, Kamoshida Toshiro, Ogawa Tatsunori, Abe Haruka, Suzuki Shunichi, Saitou Yoshiko, Aoyama Yoshifumi

doi:10.2957/kanzo.62.47

Bibliographic Information

Other Title

グレカプレビル水和物/ピブレンタスビル投与時に発現するビリルビン値上昇の重症度に影響を与えるリスク因子
グレカプレビルスイワブツ/ピブレンタスビルトウヨジニハツゲンスルビリルビンチジョウショウノジュウショウドニエイキョウオアタエルリスクインシ

Search this article

Abstract

Objective: The aim of this study was to determine factors affecting the degree of bilirubin elevation during the administration of glecaprevir (GLE) and pibrentasvir (PIB).Methods: A total of 69 patients who underwent GLE/PIB therapy were included.Results: After the administration of GLE/PIB, hyperbilirubinemia of grade 1 or greater was observed in 38 patients (55.1%). The post-treatment level of bilirubin was significantly associated with its pre-treatment level (r = 0.550, p < 0.01). Among various post-treatment variables included in a univariate analysis of the grades 0-1 and grades 2-3 groups, the pretreatment bilirubin level was identified as a risk factor for hyperbilirubinemia (p = 0.021). The multivariate analysis that was performed to eliminate the effects of confounding factors demonstrated that the pre-treatment bilirubin level was independently associated with the degree of bilirubin elevation (OR: 10.9, 95% CI: 1.866-63.781 p = 0.008).Conclusion: The pretreatment level of bilirubin is a risk factor for hyperbilirubinemia during GLE/PIB treatment.

Journal

Kanzo

Kanzo 62 (2), 47-54, 2021-02-01

The Japan Society of Hepatology

Keywords

Details 詳細情報について

Export